Market Overview

5 Pharmaceutical Price Target Raises From Jefferies


Jefferies' Jeffrey Holford raised five pharmaceuticals following key news on each company's products:

  • Abbott (NYSE: ABT) increased the price target to $45.00 after Abbot reported positive results from Type-1 Diabetes study. The study showed that Abbott system's significantly reduced Hypoglycemia.
  • Bristol-Myers Squibb Company (NYSE: BMY) raised the price objective to $78.00 after the company announced new data demonstrating continued research expansion and Immuno-Oncology Advancements across multiple blood cancers. Additionally, Bristo-Myers Squibb announced new data on Opdivo which indicated benefit in heavily pre-treated classical Hodgkin Lymphoma Patients in Phase 2.
  • Johnson and Johnson (NYSE: JNJ) price target raised to $109.00 after it announced EPREX demonstrated effectiveness as treatment for Anaemia in patients with low or intermediate-1 risk of Myelodysplastic syndromes at EHA Saturday.
  • Pfizer (NYSE: PFE)'s price target rose to $42.00 after the company announced two pivotal phase 3 studies for Ertuglifozin Met Primary Endpoints, showing significant A1C reductions in patients with Type 2 Diabetes at the American Diabetes Association's 76th scientific sessions Sunday.
  • Zoetis (NYSE: ZTS) increased the price objective to $58.00 after Zoetis shares rose considerably over the last three months.

Latest Ratings for ABT

Jun 2019MaintainsOutperform
Jan 2019MaintainsOverweightOverweight
Jan 2019DowngradesNeutralSell

View More Analyst Ratings for ABT
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color News Price Target FDA Analyst Ratings


Related Articles (ABT + BMY)

View Comments and Join the Discussion!

Social Data Show No Signs Of Recovery For Chipotle

In Wake Of Orlando Shooting, Here Are Some Positive Business Responses